ARCB vs HTZ

ArcBest Corporation's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability. The absence of an Altman Z-Score raises concern about potential distress risk, especially given a current ratio of 0.95 and quick ratio of 0.79, both below safe thresholds. Despite a seemingly attractive forward P/E of 11.68, the company exhibits negative revenue growth (-2.90% YoY) and severe earnings declines (YoY EPS down 72.9%), undermining long-term sustainability. The Graham Number of $58.46 suggests a defensive fair value, yet the stock trades at $84.87—over 44% above this benchmark—indicating significant overvaluation. Analysts' 'buy' recommendation appears misaligned with deteriorating fundamentals.

HTZ exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -4.29, indicating negative shareholder equity. While the stock has experienced a speculative short-term price surge, the fundamental health is critical with a Current Ratio of 0.57 and a Quick Ratio of 0.32, signaling significant liquidity risks. Furthermore, the current market price of $6.32 trades at a substantial premium to the analyst target price of $4.33. The combination of stagnant revenue growth and volatile, predominantly negative earnings suggests a high risk of further capital erosion.